Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pivotal phase I pharmacokinetic study of bevacizumab biosimilar (ONS-1045) compared with Avastin in volunteers

Next Previous
Trial Profile

Pivotal phase I pharmacokinetic study of bevacizumab biosimilar (ONS-1045) compared with Avastin in volunteers

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 22 Feb 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bevacizumab (Primary)
  • Indications Colorectal cancer; Lung cancer
  • Focus First in man; Pharmacokinetics; Registrational
  • Sponsors Outlook Therapeutics

Most Recent Events

  • 05 Oct 2015 Primary endpoint (Area under the time-concentration curve from first time point extrapolated to infinity) has been met, according to Oncobiologics media release.
  • 20 Apr 2015 New trial record
  • 15 Apr 2015 Dosing in this pivotal study has been completed, according to an Oncobiologics media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top